Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Gilead Sciences, Inc.NASDAQ: GILD

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin narrows to -134.5%

Net margin was -134.5% in Q2 FY2026, down 162.2 pp from a year earlier. On a trailing-twelve-month basis it was -10.6%, down 32.5 pp year over year. Over 3 fiscal years it widened by 12.1 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 18 analysts of -4.0% for the fiscal year ending Dec 2026, down from 28.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-134.5%-163.5 pp QoQ
Last fiscal yearDec 2025
28.9%+27.2 pp YoY
LTMJun 2026
-10.6%-32.5 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-162.2 pp-4.2 pp+158.0 pp
1 year+27.2 pp-32.9 pp-60.1 pp
3 years+12.1 pp+9.8 pp-2.3 pp
5 years+13.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
28.9%
Year-over-year change
+27.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How GILD compares with its peers on the latest reported figures

  • GILD's LTM Jun 2026 net margin of -10.6% is the lowest of the 10 companies compared; the peer median is 15.7%.
  • Its year-over-year change of -32.5 pp is the lowest of 10, against a peer median of -1.8 pp.
  • Over three fiscal years its change of +12.1 pp compares with a peer median of +3.6 pp.
GILD Competitors Peer median
Net Margin for GILD and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202633.5% +7.6 pp+9.8 pp
NVSNovartis AGLTM Jun 202622.9% -1.8 pp+9.6 pp
AZNAstraZeneca PLCLTM Sep 202617.7% +1.5 pp+10.0 pp
JNJJohnson & JohnsonLTM Sep 202616.2% -11.1 pp+6.0 pp
ABBVAbbVie Inc.LTM Sep 202615.7% +11.7 pp-13.5 pp
GSKGSK plcLTM Jun 202614.5% +3.7 pp-33.5 pp
SNYSanofiLTM Jun 20268.1% -13.1 pp-3.9 pp
PFEPfizer Inc.LTM Jun 20266.8% -10.0 pp-18.6 pp
MRKMerck & Co., Inc.LTM Jun 20264.8% -21.0 pp+3.6 pp
GILDGilead Sciences, Inc.LTM Jun 2026-10.6% -32.5 pp+12.1 pp
Peer median (excluding GILD) 15.7%-1.8 pp+3.6 pp

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.31B27.28B27.12B28.75B29.44B
Cost of Revenue6.6B5.66B6.5B6.25B6.23B
Gross Profit20.7B21.62B20.62B22.5B23.21B
Gross Margin75.8%79.3%76.0%78.3%78.8%
Research & Development4.6B4.98B5.72B5.91B5.8B
Selling, General & Admin5.25B5.67B6.09B6.09B5.71B
Operating Expenses10.79B14.29B13.01B20.84B11.51B
Depreciation & Amortization2.05B2.1B2.69B2.77B2.76B
EBITDA11.33B8.85B10.5B4.43B13.58B
EBITDA Margin41.5%32.4%38.7%15.4%46.1%
Operating Income9.92B7.33B7.61B1.66B11.7B
Operating Margin36.3%26.9%28.0%5.8%39.7%
Interest Income0106M376M281M349M
Interest Expense1B935M944M977M1.02B
Other Income / Expenses(1.64B)(1.52B)(746M)(972M)(1.91B)
Income Before Tax8.28B5.81B6.86B690M9.8B
Pre-Tax Margin30.3%21.3%25.3%2.4%33.3%
Income Tax Expense2.08B1.25B1.25B211M1.29B
Net Income6.23B4.59B5.67B480M8.51B
Net Margin22.8%16.8%20.9%1.7%28.9%
EPS (Basic)4.963.664.540.386.84
EPS (Diluted)4.933.644.500.386.78
Weighted Avg Shares1.26B1.26B1.25B1.25B1.24B
Weighted Avg Shares (Diluted)1.26B1.26B1.26B1.26B1.26B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.